Open access · CC-BY
via OpenAlex
Galactose‐modified duocarmycin prodrugs as senolytics
Ana T.G. Guerrero, Romain Guiho, Nicolás Herranz, Anthony G. Uren, Dominic J. Withers, Juan Pedro Martínez-Barberá, Lutz Friedjan Tietze, Jesús Gil
Aging Cell · 2020 · ▲ 174 citations
Abstract
Senescence(definition) is a stable growth arrest that impairs the replication of damaged, old or preneoplastic cells, therefore contributing to tissue homeostasis. Senescent cells accumulate during ageing and are associated with cancer, fibrosis and many age-related pathologies. Recent evidence suggests that the selective elimination of senescent cells can be effective on the treatment of many of these senescence-associated diseases. A universal characteristic of senescent cells is that they display elevated activity of the lysosomal β-galactosidase, and this has been exploited as a marker for senescence (senescence-associated β-galactosidase activity). Consequently, we hypothesized that galactose-modified cytotoxic prodrugs will be preferentially processed by senescent cells, resulting in their selective killing. Here, we show that different galactose-modified duocarmycin (GMD) derivatives preferentially kill senescent cells. GMD prodrugs induce selective apoptosis of senescent cells in a lysosomal β-galactosidase (GLB1)-dependent manner. GMD prodrugs can eliminate a broad range of senescent cells in culture, and treatment with a GMD prodrug enhances the elimination of bystander senescent cells that accumulate upon whole-body irradiation treatment of mice. Moreover, taking advantage of a mouse model of adamantinomatous craniopharyngioma (ACP), we show that treatment with a GMD prodrug selectively reduced the number of β-catenin-positive preneoplastic senescent cells. In summary, the above results make a case for testing the potential of galactose-modified duocarmycin prodrugs to treat senescence-related pathologies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/acel.13133
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Guerrero, A.T., Guiho, R., Herranz, N., Uren, A.G., Withers, D.J., Martínez-Barberá, J.P., Tietze, L.F., & Gil, J. (2020). Galactose‐modified duocarmycin prodrugs as senolytics. <em>Aging Cell</em>. https://doi.org/10.1111/acel.13133
Vancouver
Guerrero AT, Guiho R, Herranz N, Uren AG, Withers DJ, Martínez-Barberá JP, et al. Galactose‐modified duocarmycin prodrugs as senolytics. Aging Cell. 2020. doi:10.1111/acel.13133.
BibTeX
@article{ana2020Galact,
title = {Galactose‐modified duocarmycin prodrugs as senolytics},
author = {Ana T.G. Guerrero and Romain Guiho and Nicolás Herranz and Anthony G. Uren and Dominic J. Withers and Juan Pedro Martínez-Barberá and Lutz Friedjan Tietze and Jesús Gil},
journal = {Aging Cell},
year = {2020},
doi = {10.1111/acel.13133},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
bioRxiv (Cold Spring Harbor Laboratory) 2019
Preprint · CC-BY
Galactose-modified duocarmycin prodrugs as senolytics
Biomedicine & Pharmacotherapy 2021
Open access · CC-BY
Evidence and perspectives of cell senescence in neurodegenerative diseases
International Journal of Molecular Sciences 2023
Open access · CC-BY
Identification of Senescent Cells in Peri-Implantitis and Prevention of Mini-Implant Loss Using Senolytics
Nature Reviews Endocrinology 2023
Citation only
Targeting senescent cells in ageing-related endocrine diseases
npj Aging and Mechanisms of Disease 2018
Open access · CC-BY
Blocking negative effects of senescence in human skin fibroblasts with a plant extract
Metabolites 2024
Open access · CC-BY